Cargando…
Development of a Coxsackievirus A16 neutralization assay based on pseudoviruses for measurement of neutralizing antibody titer in human serum
Serum neutralizing antibody titers are indicative of protective immunity against Coxsackievirus A16 (CV-A16) and Enterovirus 71 (EV71), the two main etiological agents of hand, foot and mouth disease (HFMD), and provide the basis for evaluating vaccine efficacy. The current CV-A16 neutralization ass...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier B.V.
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7112850/ https://www.ncbi.nlm.nih.gov/pubmed/23178532 http://dx.doi.org/10.1016/j.jviromet.2012.11.014 |
_version_ | 1783513556773240832 |
---|---|
author | Jin, Jun Ma, Hongxia Xu, Lin An, Dong Sun, Shiyang Huang, Xueyong Kong, Wei Jiang, Chunlai |
author_facet | Jin, Jun Ma, Hongxia Xu, Lin An, Dong Sun, Shiyang Huang, Xueyong Kong, Wei Jiang, Chunlai |
author_sort | Jin, Jun |
collection | PubMed |
description | Serum neutralizing antibody titers are indicative of protective immunity against Coxsackievirus A16 (CV-A16) and Enterovirus 71 (EV71), the two main etiological agents of hand, foot and mouth disease (HFMD), and provide the basis for evaluating vaccine efficacy. The current CV-A16 neutralization assay based on inhibition of cytopathic effects requires manual microscopic examination, which is time-consuming and labor-intensive. In this study, a high-throughput neutralization assay was developed by employing CV-A16 pseudoviruses expressing luciferase for detecting infectivity in rhabdomyosarcoma (RD) cells and measuring serum viral neutralizing antibodies. Without the need to use infectious CV-A16 strains, the neutralizing antibody titer against CV-A16 could be determined within 15 h by measuring luciferase signals by this assay. The pseudovirus CV-A16 neutralization assay (pCNA) was validated by comparison with a conventional CV-A16 neutralization assay (cCNA) in testing 174 human serum samples collected from children (age <5 years). The neutralizing antibody titers determined by these two assays were well correlated (R(2) = 0.7689). These results suggest that the pCNA can serve as a rapid and objective procedure for the measurement of neutralizing antibodies against CV-A16. |
format | Online Article Text |
id | pubmed-7112850 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | Elsevier B.V. |
record_format | MEDLINE/PubMed |
spelling | pubmed-71128502020-04-02 Development of a Coxsackievirus A16 neutralization assay based on pseudoviruses for measurement of neutralizing antibody titer in human serum Jin, Jun Ma, Hongxia Xu, Lin An, Dong Sun, Shiyang Huang, Xueyong Kong, Wei Jiang, Chunlai J Virol Methods Article Serum neutralizing antibody titers are indicative of protective immunity against Coxsackievirus A16 (CV-A16) and Enterovirus 71 (EV71), the two main etiological agents of hand, foot and mouth disease (HFMD), and provide the basis for evaluating vaccine efficacy. The current CV-A16 neutralization assay based on inhibition of cytopathic effects requires manual microscopic examination, which is time-consuming and labor-intensive. In this study, a high-throughput neutralization assay was developed by employing CV-A16 pseudoviruses expressing luciferase for detecting infectivity in rhabdomyosarcoma (RD) cells and measuring serum viral neutralizing antibodies. Without the need to use infectious CV-A16 strains, the neutralizing antibody titer against CV-A16 could be determined within 15 h by measuring luciferase signals by this assay. The pseudovirus CV-A16 neutralization assay (pCNA) was validated by comparison with a conventional CV-A16 neutralization assay (cCNA) in testing 174 human serum samples collected from children (age <5 years). The neutralizing antibody titers determined by these two assays were well correlated (R(2) = 0.7689). These results suggest that the pCNA can serve as a rapid and objective procedure for the measurement of neutralizing antibodies against CV-A16. Elsevier B.V. 2013-02 2012-11-20 /pmc/articles/PMC7112850/ /pubmed/23178532 http://dx.doi.org/10.1016/j.jviromet.2012.11.014 Text en Copyright © 2012 Elsevier B.V. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Article Jin, Jun Ma, Hongxia Xu, Lin An, Dong Sun, Shiyang Huang, Xueyong Kong, Wei Jiang, Chunlai Development of a Coxsackievirus A16 neutralization assay based on pseudoviruses for measurement of neutralizing antibody titer in human serum |
title | Development of a Coxsackievirus A16 neutralization assay based on pseudoviruses for measurement of neutralizing antibody titer in human serum |
title_full | Development of a Coxsackievirus A16 neutralization assay based on pseudoviruses for measurement of neutralizing antibody titer in human serum |
title_fullStr | Development of a Coxsackievirus A16 neutralization assay based on pseudoviruses for measurement of neutralizing antibody titer in human serum |
title_full_unstemmed | Development of a Coxsackievirus A16 neutralization assay based on pseudoviruses for measurement of neutralizing antibody titer in human serum |
title_short | Development of a Coxsackievirus A16 neutralization assay based on pseudoviruses for measurement of neutralizing antibody titer in human serum |
title_sort | development of a coxsackievirus a16 neutralization assay based on pseudoviruses for measurement of neutralizing antibody titer in human serum |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7112850/ https://www.ncbi.nlm.nih.gov/pubmed/23178532 http://dx.doi.org/10.1016/j.jviromet.2012.11.014 |
work_keys_str_mv | AT jinjun developmentofacoxsackievirusa16neutralizationassaybasedonpseudovirusesformeasurementofneutralizingantibodytiterinhumanserum AT mahongxia developmentofacoxsackievirusa16neutralizationassaybasedonpseudovirusesformeasurementofneutralizingantibodytiterinhumanserum AT xulin developmentofacoxsackievirusa16neutralizationassaybasedonpseudovirusesformeasurementofneutralizingantibodytiterinhumanserum AT andong developmentofacoxsackievirusa16neutralizationassaybasedonpseudovirusesformeasurementofneutralizingantibodytiterinhumanserum AT sunshiyang developmentofacoxsackievirusa16neutralizationassaybasedonpseudovirusesformeasurementofneutralizingantibodytiterinhumanserum AT huangxueyong developmentofacoxsackievirusa16neutralizationassaybasedonpseudovirusesformeasurementofneutralizingantibodytiterinhumanserum AT kongwei developmentofacoxsackievirusa16neutralizationassaybasedonpseudovirusesformeasurementofneutralizingantibodytiterinhumanserum AT jiangchunlai developmentofacoxsackievirusa16neutralizationassaybasedonpseudovirusesformeasurementofneutralizingantibodytiterinhumanserum |